| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6192481 | Journal of Thoracic Oncology | 2016 | 13 Pages |
Abstract
ROS1 fusion positivity is probably a favorable factor of pemetrexed-based therapy for patients with lung adenocarcinoma.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yen-Fu MD, Min-Shu MD, Shang-Gin MD, Yih-Leong MD, Chong-Jen MD, PhD, James Chih-Hsin MD, PhD, Pan-Chyr MD, PhD, Jin-Yuan MD, PhD,